Muscular Diseases  >>  Soliris (eculizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT00005571: Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis

Completed
2
17
US
h5G1.1-mAb
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Dermatomyositis
 
12/01

Download Options